rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2006-3-27
|
pubmed:abstractText |
Although nifekalant is a class III antiarrhythmic agent without negative inotropic activity, its effect in patients with shock-refractory ventricular fibrillation remains unclear.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1346-9843
|
pubmed:author |
pubmed-author:EbinaToshiakiT,
pubmed-author:HibiKiyoshiK,
pubmed-author:KimuraKazuoK,
pubmed-author:KosugeMasamiM,
pubmed-author:KosugeTakayukiT,
pubmed-author:MoriwakiYoshihiroY,
pubmed-author:SugiyamaMitsugiM,
pubmed-author:SumitaShinichiS,
pubmed-author:SuzukiNoriyukiN,
pubmed-author:TaharaYoshioY,
pubmed-author:ToyamaHideshiH,
pubmed-author:UmemuraSatoshiS
|
pubmed:issnType |
Print
|
pubmed:volume |
70
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
442-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16565562-Aged,
pubmed-meshheading:16565562-Anti-Arrhythmia Agents,
pubmed-meshheading:16565562-Cardiopulmonary Resuscitation,
pubmed-meshheading:16565562-Epinephrine,
pubmed-meshheading:16565562-Female,
pubmed-meshheading:16565562-Heart Arrest,
pubmed-meshheading:16565562-Humans,
pubmed-meshheading:16565562-Lidocaine,
pubmed-meshheading:16565562-Male,
pubmed-meshheading:16565562-Middle Aged,
pubmed-meshheading:16565562-Multivariate Analysis,
pubmed-meshheading:16565562-Pyrimidinones,
pubmed-meshheading:16565562-Retrospective Studies,
pubmed-meshheading:16565562-Survival Rate,
pubmed-meshheading:16565562-Time Factors,
pubmed-meshheading:16565562-Ventricular Fibrillation
|
pubmed:year |
2006
|
pubmed:articleTitle |
Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation.
|
pubmed:affiliation |
Division of Critical Care and Emergency Medicine, Yokohama City University Medical Center, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|